P530: Proactive therapeutic drug monitoring of anti-TNF agents is associated with higher mucosal healing rates in Crohn's diseaseECCO'21 VirtualYear: 2021
Authors: Brinar, M.(1);Sabic , M.(1);Turk , N.(1);Grgic, D.(1);Domislovic, V.(1);Cukovic Cavka, S.(1);Kozmar, A.(2);Krznaric, Z.(1);
(1)University Hospital Zagreb, Gastroenterology and Hepatology, Zagreb, Croatia;(2)University Hospital Zagreb, Clinical Institute for Laboratory Diagnosis, Zagreb, Croatia
P531: SARS-CoV-2 infection in Elderly patients with Inflammatory Bowel Disease with or without immunosuppressants during the first year of the pandemic. An observational, descriptive, cohort study.ECCO'21 VirtualYear: 2021
Authors: Calafat Sard, M.(1,2);González-Muñoza: , C.(3); Fortuny, M.(1);Roig, C.(3);Calm, A.(1);Mombiela, A.(3);Teller-Martin, M.(3);Cañete:, F.(1,2);Bertoletti, F.(3);González-González, L.(1);Gordillo, J.(3);Mañosa, M.(1,2);Garcia-Planella , E.(3);Domènech, E.(1,2);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain;(2)Ciberehd, Ciberehd, Madrid, Spain;(3)Hospital de la Santa Creu i Sant Pau, Gastroenterology Department, Barcelona, Spain
P532: Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemicECCO'21 VirtualYear: 2021
Authors: Guo, H.(1);Tang, J.(1);Huang, Z.(1);Li, B.(1);Yang, Q.(1);Chao, K.(1);Gao, X.(1);
(1)the Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China
P533: Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practiceECCO'21 VirtualYear: 2021
Authors: Calvo Moya, M.I.(1);Omella Usieto, I.(2);El Hajra Martinez, I.(2);Santos Perez, E.(2);Gonzalez Lama, Y.(1);Ruiz Antoran, B.(3);Menchen Viso, B.(4);Matallana Royo, V.(1);Gonzalez Partida, I.(1);De Lucas Tellez de Meneses, R.(1);Bella del Castillo, P.(1);Gonzalez Rodriguez, M.(1);Vera Mendoza, M.I.(1);
(1)Hospital Universitario Puerta de Hierro - Majadahonda, IBD Unit. Gastroenterology and Hepatology, Madrid, Spain;(2)Hospital Universitario Puerta de Hierro - Majadahonda, Gastroenterology and Hepatology, Madrid, Spain;(3)Hospital Universitario Puerta de Hierro - Majadahonda, Clinical Pharmacology, Madrid, Spain;(4)Hospital Universitario Puerta de Hierro - Majadahonda, Hospital Pharmacy, Madrid, Spain
P534: Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in Russia: results of the EXPLORE studyECCO'21 VirtualYear: 2021
Authors: Shapina, M.(1);
(1)State Scientific Centre of Coloproctology named after A.N.Ryzhih- Moscow- Russia, Gastroenterology, Moscow, Russian Federation; Authors: Abdulganieva D.I.1 Chashkova E.Y.2 Gubonina I.V.3 Schukina O.B.4 Shapina M.V.5 1Kazan State Medical University Kazan Russia 2 Irkutsk Scientific Center of Surgery and Traumatology Irkutsk Russia 3S.M. Kirov Military Medical Academy Saint-Petersburg Russia 4North-Western State Medical University named after I.I. Mechnikov Saint-Petersburg Russia 5State Scientific Centre of Coloproctology named after A.N.Ryzhih Moscow Russia
P535: Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidenceECCO'21 VirtualYear: 2021
Authors: Louis, E.(1);Nikolaou, A.(2);Litkiewicz, M.(2);Agboton, C.(3);Wang, S.(4);Armuzzi, A.(5);
(1)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(2)Evidera, Modelling and Simulation, London, United Kingdom;(3)Takeda, Global Medical Affairs - Gastroenterology, Zurich, Switzerland;(4)Takeda, Global Evidence & Outcomes - Gastroenterology, Cambridge, United States;(5)Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica, Gastroenterology Unit CEMAD, Rome, Italy
P537: Anemia in Crohn's Disease: Response to treatment and risk of recurrenceECCO'21 VirtualYear: 2021
Authors: Gharbi, G.(1);Bibani, N.(1);Sabbah, M.(1);Nawel, B.(1);Trad, D.(1);Ouakaa, A.(1);Elloumi, H.(1);Gargouri, D.(1);
(1)Habib Thameur Hospital, Gastroenterology, tunis, Tunisia
P538: The reliability of patient performed fecal calprotectin testingECCO'21 VirtualYear: 2021
Authors: Crouwel, F.(1);Dijkhuis, L.E.J.L.(1);Duijvestein, M.(1);Buiter, H.J.C.(2);De Boer, N.K.(1);Hamer, H.M.(3);
(1)Amsterdam UMC- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- location VUmc, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC- location VUmc, Department of Clinical Chemistry, Amsterdam, The Netherlands
P539: Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US)ECCO'21 VirtualYear: 2021
Authors: Afzali, A.(1);Kakehi, S.(2);Lapensee, K.(2);Lukanova, R.(3);Hennessy, F.(3);Knight, H.(3);Singh, K.(2);
(1)The Ohio State University Wexner Medical Center, Gastroenterology, Columbus, United States;(2)Bristol Myers Squibb, Health Economics and Outcomes Research, Princeton, United States;(3)Adelphi Real World, Gastroenterology, Bollington, United Kingdom
P540: Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literatureECCO'21 VirtualYear: 2021
Authors: Singh, H.(1);Wilson, L.(2);Pandey, A.(3);Tencer, T.(4);Kumar, J.(4);
(1)Amaris Consulting Ltd, Health Economics & Market Access HEMA, Toronto, Canada;(2)Amaris Consulting Ltd, Health Economics & Market Access HEMA, Shanghai, China;(3)Amaris Consulting Ltd, Health Economics & Market Access HEMA, London, United Kingdom;(4)Bristol Myers Squibb, Global HEOR, Princeton, United States
P541: Efficacy, efficiency and aceptability of telemedicine for inflammatory bowel disease patients follow-up care during the COVID-19 pandemic lockdown.ECCO'21 VirtualYear: 2021
Authors: Ramos Lopez, L.(1);Reygosa, C.(1);Carrillo-Palau, M.(1);Alonso-Abreu, I.(1);González, Y.(1);de la Barreda, R.(1);Amaral , C.(1);Hernández, A.(1);Benítez-Zafra, F.(1);Hernández-Guerra, M.(1);
(1)Hospital Universitario De Canarias, Department of Gastroenterology, Santa Cruz De Tenerife, Spain
P543: The role of social support on psychological distress and health-related quality of life in adults with mild to moderately active Crohn's disease.ECCO'21 VirtualYear: 2021
Authors: Regev, S.(1);Goren, G.(1);Schwartz, D.(2);Sergienko , R.(3);Friger, M.(4);Nemirovsky , A.(5);Greenberg, D.(6);Monsonego, A.(7);Sarid, O.(1);Slonim-Nevo, V.(1);Odes, S..(8);
(1)Ben-Gurion University of the Negev- Beer Sheva- Israel, Spitzer Department of Social Work, Beer Sheva, Israel;(2)Faculty of Health Sciences- Ben-Gurion University of the Negev- and Soroka Medical Center -Beer-Sheva- Israel, Department of Gastroenterology and Hepatology, Beer Sheva, Israel;(3)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department. of Public Health, Beer Sheva, Israel;(4)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Public Health, Beer Sheva, Israel;(5)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, The Shraga Segal Department of Microbiology- Immunology- and Genetics, Beer Sheva, Israel;(6)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Health Systems Management- School of Public Health- Guilford Glazer Faculty of Business and Management, Beer Sheva, Israel;(7)Ben-Gurion University of the Negev- Beer-Sheva- Israel, The Shraga Segal Department of Microbiology- Immunology- and Genetics- Faculty of Health Sciences- and The National Institute of Biotechnology in the Negev, Beer Sheva, Israel;(8)Faculty of Health Sciences- Ben-Gurion University of the Negev- Beer-Sheva- Israel, Department of Gastroenterology and Hepatology, Beer Sheva, Israel
P544: Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrationsECCO'21 VirtualYear: 2021
Authors: Volkers, A.(1);Löwenberg, M.(1);Bray, K.(2);Bahur, B.(2);Braad, M.(1);Abeling, Y.(1);Gecse, K.(1);Duijvestein, M.(1);Ponsioen, C.(1);D'Haens, G.(1);
(1)AmsterdamUMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)ProciseDx, Clinical Dev & Medical Affairs, San Diego, United States
P545: Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with VedolizumabECCO'21 VirtualYear: 2021
Authors: Rubstov, D.(1);Kakkadasam Ramaswamy, P.(1);Edwards, J.(1);Shukla, D.(1);Willmann, L.(1);Moattar, H.(1);Bhullar, M.(1);Ishaq, N.(1);Dorrington, A.(1);Mohsen, W.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Southport, Australia
P547: Safety and efficacy of vedolizumab in the treatment of patients with moderate to severe Ulcerative Colitis: a systematic review and meta-analysisECCO'21 VirtualYear: 2021
Authors: KhorshidFASGE, M.(1);Alboraie, M.(2);Abbas, W.(3);Sayed, Z.E.(3);El-Nady, M.(4);
(1)EDGE Foundation, Department of Clinical Research, Cairo, Egypt;(2)Al-Azhar University, Department of Internal Medicine, Cairo, Egypt;(3)Assiut University, Department of Internal Medicine, Assiut, Egypt;(4)Cairo University, Department of Internal Medicine, Cairo, Egypt
P548: Drug Survival in Patients with Inflammatory Bowel disease: An observational studyECCO'21 VirtualYear: 2021
Authors: Kubesch, A.(1);Grimm, L.(1);Stratmann, K.(1);Knabe, M.(1);Filmann, N.(2);Sprinzl, K.(1);Hausmann, J.(1);Blumenstein, I.(1);
(1)Goethe-University Hospital, Department of Internal Medicine 1, Frankfurt, Germany;(2)Goethe-University Hospital, Institute of Biostatistics and Mathematical Modeling, Frankfurt, Germany
